In an adult woman with pattern hair loss, which is the preferred therapy for hair regrowth: topical minoxidil, hormonal therapy (HERS), or neutrophil‑based treatment?

Treatment of Female Pattern Hair Loss: Minoxidil vs. Hormonal Therapy vs. Neutrophil-Based Treatment

Direct Answer

Topical minoxidil 5% twice daily is the established first-line treatment for female pattern hair loss, and for patients with suboptimal response, adding platelet-rich plasma (PRP) injections provides superior efficacy compared to minoxidil alone. 1, 2

---

First-Line Treatment: Topical Minoxidil

Topical minoxidil 5% applied twice daily is the only FDA-approved treatment for female androgenetic alopecia and remains the gold standard with the highest level of evidence. 1, 2, 3

• Minoxidil must be continued indefinitely to maintain results, as discontinuation leads to reversal of hair growth benefits within months 1, 2
• Realistic timelines require 6-12 months for visible improvement; hair regrowth cannot be expected within 3 months 2
• Approximately 40-60% of women respond adequately to 5% minoxidil monotherapy, meaning a substantial proportion will need additional interventions 4, 3

---

Second-Line Treatment: Combination Therapy with PRP

For women who show suboptimal response to minoxidil alone after 6 months, adding PRP injections to continued topical minoxidil provides the most effective treatment approach. 1, 2

Evidence for Combination Superiority

• The combination of PRP with topical minoxidil 5% achieves a 57% median increase in terminal hair density versus 48% with minoxidil alone at 32 weeks 1
• Complex therapy (PRP with minoxidil) increased hair density by 1.74 times compared to minoxidil monotherapy 2
• 83% of patients achieve a negative hair pull test (indicating reduced hair fragility) with combination therapy 1

PRP Treatment Protocol

Use the following evidence-based protocol for optimal results: 1

• Preparation: Manual double-spin method with target platelet concentration of 1-1.5 million platelets per µL 1
• Activation: Use nonactivated PRP, which shows 31% greater improvement in hair density compared to activated PRP 1
• Initial phase: Minimum of 3-5 sessions at 1-month intervals 1
• Dose: 5-7 mL PRP per session, using 0.05 to 0.1 mL/cm² 1
• Injection technique: 90-degree angle, 2-4 mm depth, injections 1 cm apart, using 30G × 4 mm needles 1
• Maintenance phase: 1 session every 6 months after initial treatment 1
• Pain management: Apply pharmaceutical-grade topical anesthetic cream before injection due to significant pain 1

Patient Preparation

• Patient must shampoo and detangle hair before session, with no hair products applied 1
• Maximum response is typically achieved by 6 months, with regular monitoring required 1

---

Monitoring Treatment Efficacy

Evaluate treatment response using multiple objective methods: 1

• Standardized before-and-after photographs 1
• Trichoscopy to evaluate hair density and diameter 1
• Hair pull tests to evaluate hair fragility 1
• Patient self-assessment questionnaires 1
• Key indicators include increased hair density, increased hair shaft diameter, decreased proportion of telogen hairs, and improved patient satisfaction scores 1

---

Alternative Options for Minoxidil-Intolerant Patients

For patients who cannot tolerate or comply with topical minoxidil, oral minoxidil 1 mg daily may be considered, but requires mandatory cardiovascular screening. 2, 5

Oral Minoxidil Considerations

• Oral minoxidil 1 mg is as effective as topical 5% minoxidil for pattern hair loss 2, 5
• Contraindicated in women with pre-existing cardiovascular disease 5
• Screen all patients for cardiovascular disease before initiation, including assessment for orthostatic symptoms, edema, and tachycardia 2, 5
• Women have a higher overall incidence of adverse effects compared to men and require lower starting doses 2, 5
• Common side effects include hypertrichosis (17.5%), edema of lower limbs, and orthostatic hypotension 5
• Rare but serious adverse effects include pericardial effusion and tachycardia (3.5%) 5
• Must be avoided in pregnancy or women planning to become pregnant 5

---

Adjunctive Therapy: Low-Level Laser Therapy

Low-level laser therapy (LLLT) with 655-nm laser devices can be used as adjunctive therapy, applied three times per week. 1, 2

• Continuous, indefinite use is required to maintain achieved regrowth 1
• Abrupt cessation results in loss of hair-regrowth gains within months 1
• Use FDA-cleared 655 nm laser devices specifically marketed for hair regrowth 1

---

Emerging Treatment: Platelet-Rich Fibrin (PRF)

PRF shows promise as a potentially superior alternative to PRP with theoretical advantages, though high-quality comparative data are currently lacking. 6, 2

• PRF contains a longer release of growth factors compared to PRP and functions as both a scaffold and reservoir 6
• Theoretical advantages include lower cost, easier preparation, and sustained growth factor release 2
• Preliminary studies demonstrate safety and efficacy comparable to PRP 1
• No randomized controlled trials are available to date comparing PRF to PRP 6

---

Addressing "HERS" and "Neutrophil" Treatments

There is no established treatment called "HERS" or "neutrophil-based treatment" for female pattern hair loss in the medical literature or guidelines.

• If "HERS" refers to hormonal therapy, oral antiandrogens (such as spironolactone) demonstrate some efficacy but are not first-line therapy and have significant considerations for side effects and contraindications 7
• The exact role of androgens in female pattern hair loss remains unclear, unlike in male androgenetic alopecia 7
• If "neutrophil" refers to platelet-rich plasma or platelet-rich fibrin (which contain white blood cells including neutrophils), see the PRP/PRF sections above

---

Critical Pitfalls to Avoid

Low platelet concentration, inadequate injection volume, or insufficient treatment frequency leads to PRP treatment failure. 2

• Individual genetic factors significantly influence response to all treatments 2
• Inadequate follow-up to assess treatment response leads to suboptimal outcomes 1
• Insufficient treatment duration can lead to suboptimal outcomes, with some patients requiring extended therapy beyond initial 6 months 1
• The efficacy of treatments may decrease with the severity and duration of alopecia 1

---

Treatment Algorithm

Follow this evidence-based approach:

1. Start all patients with topical minoxidil 5% twice daily as first-line therapy 1, 2
2. Evaluate response at 6 months using standardized photographs, trichoscopy, and patient assessment 1
3. If suboptimal response at 6 months, add PRP injections (3-5 monthly sessions, then maintenance every 6 months) while continuing topical minoxidil 1, 2
4. If patient cannot tolerate topical minoxidil, consider oral minoxidil 1 mg daily after cardiovascular screening 2, 5
5. Consider LLLT three times weekly as adjunctive therapy at any stage 1, 2
6. Continue all effective treatments indefinitely to maintain benefits 1, 2

---

Important Distinction: This is for Pattern Hair Loss Only

This treatment approach is specifically for androgenetic alopecia (pattern hair loss) only, and not appropriate for patchy hair loss (alopecia areata), which requires different treatment. 6, 2

• Minoxidil will not improve alopecia areata effectively, with variable response rates of only 32-33% 2
• For alopecia areata, intralesional corticosteroids or contact immunotherapy are recommended instead 6